Eton Pharmaceutical ETON 深 沪
已收盘 10-31 16:00:00 美东时间
18.01
-0.240
-1.32%
华盛通- 最 高18.53
- 今 开18.14
- 成交量 16.11万股
- 最 低 17.70
- 昨 收 18.25
- 总市值 4.83亿
- 52周最高 23.00
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 8.43
- 委 比 -11.97%
- 总股本 2681.75万
- 历史最高 23.00
- 量 比 1.04
- 振 幅 4.55%
- 历史最低 1.95
- 每 手 1
- 风险率 2.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PMV Pharmaceuticals Announces Updated Data From The Phase 2 Pivotal Portion Of The Ongoing PYNNACLE Clinical Trial In Patients With Advanced Solid Tumors Harboring A TP53 Y220C Mutation; Overall Response Rate Of 34% (35/103 Patients) Per Investigator Assessment According To Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1, Including Confirmed And Unconfirmed Responses
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung,
10-24 23:44
Soligenix Updates U.S. Medical Advisory Board To Guide Phase 3 HyBryte Development For CTCL
Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical DevelopmentPRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage
10-14 19:33
Soligenix Expands European MAB To Provide Addl Medical/Clinical Strategic Guidance As It Advances Confirmatory Phase 3 Placebo-Controlled Study Evaluating Safety And Efficacy Of HyBryte In CTCL Treatment
In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J., Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a
09-30 19:36
Soligenix Announces Pricing of $7.5 Million Public Offering
PRINCETON, N.J., Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializin...
09-26 18:33
PDS Biotech Reports 29.5-Month Median Overall Survival In Phase 2 Trial For Advanced Head And Neck Cancer; Says Encouraging Efficacy Signal Observed In Difficult To Treat Category Of Advanced Head And Neck Cancer Patients
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients with CPS
09-18 20:47
CytoSorbents Provides DrugSorb-ATR Regulatory Update
PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surge...
09-16 19:00
Miami International Holdings Launches Next-Generation Options Trading Floor in Miami
MIAMI and PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ -- Miami International Holdings, Inc. (MIAX®) (NYSE: MIAX), a technology-driven leader in building and operating regulated financial ma...
09-16 18:45
BioNTech, Bristol Myers Squibb Present Interim Data From Global Randomized Phase 2 Trial Evaluating Pumitamig, Investigational Bispecific Antibody Targeting PD-L1 X VEGF-A, Plus Chemotherapy In ES-SCLC Patients
PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer ("ES-SCLC"), expanding evidence for
09-08 23:03
Miami International Holdings Reports Trading Results for August 2025
PRINCETON, N.J. and MIAMI, Sept. 8, 2025 /PRNewswire/ -- Miami International Holdings, Inc. (NYSE: MIAX) (MIAX), a technology-driven leader in building and operating regulated financial mark...
09-08 21:15
CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference
PRINCETON, N.J., Sept. 5, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surger...
09-05 19:00
